

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q101075

Shigenori OHKAWA, et al.

Appln. No.: 10/561,483

Group Art Unit: 1609

Confirmation No.: 8172

Examiner: Havlin, Robert H.

Filed: December 20, 2005

For: CANNABINOID RECEPTOR MODULATOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents listed on the attached PTO/SB/08 A & B (modified) form, which the examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for the foreign language document (JP 2000-256323), Applicants submit the following explanation: an English-language abstract of JP 2000-256323 is included and U.S. Patent No. 6,509,352 is a family member of JP 2000-256323.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



L. Raul Tamayo
Registration No. 47,125

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 6, 2007

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/561,483
				Confirmation Number	8172
				Filing Date	December 20, 2005
				First Named Inventor	Shigenori OHKAWA
				Art Unit	1609
				Examiner Name	Havlin, Robert H.
Sheet	1	of	1	Attorney Docket Number	Q101075

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,172,085	B1	01-09-2001	OHKAWA et al.
		US 6,479,536	B1	11-12-2002	OHKAWA et al.
		US 5,376,681	A	12-27-1994	AONO et al.
		US 6,525,087	B2	02-25-2003	MITTENDORF et al.
		US 7,030,139	B2	04-18-2006	CHENG et al.
		US 6,930,118	B2	08-16-2005	MOLONEY et al.
		US 6,509,352	B1	01-21-2003	INABA et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	97/28143	A1	08-07-1997	THE PROCTER & GAMBLE COMPANY	
		EP	1 136 477	A1	09-26-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.	
		WO	96/07651	A1	03-14-1996	THE PROCTER & GAMBLE COMPANY	
		EP	1 323 716	A1	07-02-2003	TAKEDA CHEMICAL INDUSTRIES, LTD.	
		WO	96/18391	A2	06-20-1996	LIFEGROUP S.P.A.	
		WO	96/02248	A1	02-01-1996	ELI LILLY AND COMPANY	
		JP	2000-256323	A	09-19-2000	JAPAN TOBACCO INC.	English Abstract
		WO	02/085866	A1	10-31-2002	ASTRAZENECA AB	
		WO	02/036590	A1	05-10-2002	AMRAD OPERATIONS PTY LTD	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		OHKAWA et al., "5-Aminocoumarans: Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects against Central Nervous System Trauma and ischemia", J. Med. Chem. 1997, 40, pp. 559-573.	
		JANUSZ et al., "New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3. 7-tert-Butyl-2,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antinflammatory and Analgesic Agents: Variations at the 5 Position", J. Med. Chem. 1998, 41, pp. 3515-3529.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.